ArticleDiscover oncology2025
A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo identify molecular clusters and develop a novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence free survival (BCRFS) and tumor immune microenvironment of prostate cancer (PCa). MATERIALS AND
methodsWe obtained the clinical and transcriptome data of PCa from TCGA and GEO database. Univariate and multivariate Cox regression analysis were used to establish a novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting BCRFS. To evaluate the validity of the risk score, both internal and external validations were carried out. Preliminary in-vivo and in-vitro experimental validations were performed to verify the biological functions of NOG in PCa docetaxel resistance.
resultsAfter screening 67 docetaxel resistance related differentially expressed gene (DEGs), we identified three docetaxel resistance-related clusters with significantly different BCRFS, immune cell infiltration, and PD-L1 expression. More importantly, a novel docetaxel resistance-related prognostic risk score was constructed. In training, testing, and validating cohorts, the BCRFS of the patients with high-risk scores was considerably lower. The AUCs for the three cohorts were 0.767, 0.714, and 0.719, respectively. Subgroup analysis suggested that the risk score has a strong clinical value in the TIII-IV N0 or clusters 1-2 PCa patients. The expression of the NOG was significantly elevated in docetaxel-resistant PCa cells compared to the normal strain. The knockdown of the NOG reduced the IC50 of docetaxel of docetaxel-resistant PCa cells and the overexpression of NOG increased the IC50 of docetaxel and promoted the colony formation ability under docetaxel treatment of DU145 and PC-3 cells. In vivo tumorigenesis assay revealed that the overexpression of NOG could promote the tumorigenesis of PCa under docetaxel treatment.
conclusionsWe successfully identified a total of 67 docetaxel resistance related DEGs. A novel prognostic risk score associated with resistance to docetaxel chemotherapy of PCa was developed and validated, which performed well in predicting the BCRFS of PCa. High expression of NOG could promote the docetaxel resistance of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.